Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
VEFORA: Fractionated Cisplatin vs Carboplatin in Urothelial Cancer
NCT02240017Phase 3Completed
- Sponsor
- Institut Claudius Regaud
- Start
- Jan 2015
- Primary completion
- Apr 2018
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised trial of cisplatin in urothelial carcinoma (UC) (2 arms), sponsored by Institut Claudius Regaud. Primary endpoints: Rate of non progression at the end of treatment (C6D21) at 5 years, Overall Survival at 9 years and 1 more. Started Jan 2015; status: completed.
02
Drugs
cisplatin
03
Conditions
urothelial carcinoma (UC)
Beyond the preview
Go deeper on NCT02240017.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02240017.